Log in to search using one of your social media accounts:

 

European Commission Approves Bavencio (avelumab) for Metastatic Merkel Cell Carcinoma
First approved immunotherapy for rare and aggressive skin cancer in the European Union, with initial launches planned in Germany and the UK Builds on Bavencio's previous accelerated approvals in the US and recent approval in Switzerland Approval base... Biopharmaceuticals, Oncology, Regulatory Merck KGaA, Pfizer, BAVENCIO, avelumab, Merkel cell carcinoma (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - September 21, 2017 Category: Pharmaceuticals Source Type: news

Merck KGaA, Pfizer's cancer drug Bavencio gets EU nod
FRANKFURT (Reuters) - European regulators on Thursday granted market approval for Merck KGaA and Pfizer's immuno-oncology drug Bavencio to treat a rare and aggressive type of skin cancer called Merkel cell carcinoma. (Source: Reuters: Health)
Source: Reuters: Health - September 21, 2017 Category: Consumer Health News Tags: healthNews Source Type: news

EMA's CHMP Issues Positive Opinion for Avelumab for the Treatment of Metastatic Merkel Cell Carcinoma
If approved, avelumab could be the first immunotherapy treatment indicated for this rare and aggressive skin cancer in the EU Decision by the EC is expected in the third quarter of 2017 Not intended for UK-based media DARMSTADT, Germany and NEW YO... Biopharmaceuticals, Oncology, Regulatory Merck KGaA, BAVENCIO, avelumab, metastatic Merkel cell carcinoma (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - July 21, 2017 Category: Pharmaceuticals Source Type: news

Pfizer, Merck KGaA skin cancer drug gets EMA nod for approval
(Reuters) - European regulators on Friday recommended approving Pfizer Inc and Merck KGaA's immuno-oncology drug Bavencio to treat a rare type of skin cancer called Merkel cell carcinoma. (Source: Reuters: Health)
Source: Reuters: Health - July 21, 2017 Category: Consumer Health News Tags: healthNews Source Type: news

Triple immunotherapy for rare skin cancer shows promise in small, early-stage trial
(Fred Hutchinson Cancer Research Center) Combo of T-cell therapy, newly FDA-approved drug and another immunotherapeutic agent kept cancer at bay for three out of four patients with metastatic Merkel cell carcinoma. The findings will be presented June 5 at the annual meeting of the American Society of Clinical Oncology. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - May 30, 2017 Category: Cancer & Oncology Source Type: news

Revealed: How polyomavirus tricks our cells into helping it build its invasion route
(Michigan Medicine - University of Michigan) If every cell in our body is a factory, viruses are industrial spies who try to break in and take over. New findings about how one of the most mysterious types of spy - polyomaviruses -- accomplishes this feat could aid the fight against Merkel cell carcinoma, and diseases in organ transplant and cancer patients. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - May 24, 2017 Category: Cancer & Oncology Source Type: news

2 UAMS Cancer Researchers Get $1.6M
Two cancer researchers at the University of Arkansas for Medical Sciences have each received a four-year grant of $791,000 to support their work. Aime Franco and Dr. Ling Gao have been awarded Research Scholar Grants from the American Cancer Society. UAMS said the grants are among 109 national research and training grants totaling more than $45 million that will fund investigators at 75 institutions across the country. The grants go into effect July 1. "Based on our extremely rigorous peer review system, we think these two young scientists represent some of the finest cancer researchers in the country," said Char...
Source: Arkansas Business - Health Care - May 10, 2017 Category: American Health Source Type: news

Merck and Pfizer secure US FDA approval for Bavencio to treat skin cancer
Merck ’s biopharmaceutical business EMD Serono and Pfizer have obtained the US Food and Drug Administration’s (FDA) approval for a 20mg/mL Bavencio (avelumab) injection to treat patients with metastatic Merkel cell carcinoma (mMCC), a rare and aggress… (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - March 26, 2017 Category: Pharmaceuticals Source Type: news

Immunotherapy drug becomes first therapy approved by FDA for rare skin cancer
The U.S. Food and Drug Administration has granted accelerated approval to the checkpoint inhibitor Bavencio (avelumab) for the treatment of patients with metastatic Merkel cell carcinoma. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - March 24, 2017 Category: Science Source Type: news

EMD Serono nabs FDA approval for rare skin cancer drug
The FDA has approved a drug for a rare form of skin cancer that was developed in part by researchers at an EMD Serono facility in Billerica. The agency announced Thursday afternoon that it had approved avelumab, the first-ever treatment for metastatic Merkel cell carcinoma. The drug was jointly developed by German drugmaker Merck KGaA and Pfizer (NYSE: PFE), and will be sold by the companies as Bavencio. EMD Serono, based in Rockland, is the biopharma arm of Merck KGaA in the U.S. and Canada. Bavencio… (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - March 24, 2017 Category: Pharmaceuticals Authors: Max Stendahl Source Type: news

FDA approves first treatment for rare form of skin cancer
The U.S. Food and Drug Administration has granted accelerated approval to Bavencio (avelumab) for the treatment of adults and pediatric patients 12 years and older with metastatic Merkel cell carcinoma (MCC), including those who have not received prior chemotherapy. This is the first FDA-approved treatment for metastatic MCC, a rare, aggressive form of skin cancer. (Source: World Pharma News)
Source: World Pharma News - March 24, 2017 Category: Pharmaceuticals Tags: Featured FDA Regulatory Affairs Source Type: news

Immunotherapy drug becomes first therapy approved by FDA for rare skin cancer
(Fred Hutchinson Cancer Research Center) The US Food and Drug Administration yesterday granted accelerated approval to the checkpoint inhibitor Bavencio (avelumab) for the treatment of patients with metastatic Merkel cell carcinoma (MCC), including those who have not received prior chemotherapy. Avelumab is the first FDA-approved treatment for metastatic MCC and the first disease that the drug has ever been approved to treat. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - March 24, 2017 Category: Global & Universal Source Type: news

FDA Approves Drug for Rare Skin Cancer
(MedPage Today) -- Avelumab active in Merkel cell carcinoma (Source: MedPage Today Public Health)
Source: MedPage Today Public Health - March 23, 2017 Category: American Health Source Type: news

Avelumab: First Drug Ever Approved for Merkel Cell Carcinoma Avelumab: First Drug Ever Approved for Merkel Cell Carcinoma
Patients who develop this rare but aggressive skin cancer have not had a specific therapy, until today's approval of a novel immunotherapy.FDA Approvals (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - March 23, 2017 Category: Cancer & Oncology Tags: Hematology-Oncology News Alert Source Type: news

FDA approves first treatment for rare form of skin cancer
The U.S. Food and Drug Administration today granted accelerated approval to Bavencio (avelumab) for the treatment of adults and pediatric patients 12 years and older with metastatic Merkel cell carcinoma (MCC), including those who have not received prior chemotherapy. This is the first FDA-approved treatment for metastatic MCC, a rare, aggressive form of skin cancer. (Source: Food and Drug Administration)
Source: Food and Drug Administration - March 23, 2017 Category: American Health Source Type: news

Bavencio Approved for Rare Skin Cancer
THURSDAY, March 23, 2017 -- Bavencio (avelumab) has been approved by the U.S. Food and Drug Administration to treat a rare but aggressive form of skin cancer called Merkel cell carcinoma (MCC), the agency said Thursday in a news release. The drug,... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - March 23, 2017 Category: Journals (General) Source Type: news

Immune responses against a virus-related skin cancer suggest ways to improve immunotherapy
(Fred Hutchinson Cancer Research Center) Researchers at Seattle's Fred Hutchinson Cancer Research Center and the University of Washington say a new study suggests ways to improve immune therapy for certain cancers including a virus-associated form of Merkel cell carcinoma, a rare, aggressive skin cancer. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - January 17, 2017 Category: Cancer & Oncology Source Type: news

Novel test enables earlier detection of Merkel cell carcinoma, Fred Hutch scientists say
(Fred Hutchinson Cancer Research Center) New research findings show how immune system marker can supplement and often outperform imaging studies for recurrence of Merkel cell carcinoma (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - December 7, 2016 Category: Cancer & Oncology Source Type: news

When hope returns: a new drug takes on a rare, aggressive skin cancer
Fred Ewart is taking a new immunotherapy drug in the hopes it will help him survive Merkel cell carcinoma. So far, it's working. (Source: CBC | Health)
Source: CBC | Health - June 19, 2016 Category: Consumer Health News Tags: News/Health Source Type: news

No Radiation Needed in Some Patients With Merkel Cell CarcinomaNo Radiation Needed in Some Patients With Merkel Cell Carcinoma
In certain patients with small Merkel cell carcinoma tumors, surgical excision without adjuvant radiation therapy (RT) of the primary site, may be appropriate, according to researchers. Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - June 8, 2016 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Investigational immunotherapy drug well tolerated in those with rare form of melanoma
An investigational immunotherapy drug being tested in the treatment of a rare form of skin cancer known as Merkel cell carcinoma has been found to be well tolerated with a clinical benefit seen in up to 42 percent of patients who failed prior treatment and were observed for at least six months. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - June 6, 2016 Category: Science Source Type: news

Identifying how merkel cell polyomavirus infection can cause a lethal carcinoma
A benign virus normally found in the skin can lead to a type of rare, lethal skin cancer. Specifically, infection by the Merkel cell polyomavirus can lead to Merkel cell carcinoma in immune-compromised individuals. Researchers have now identified a type of skin cell as the target of the virus in humans and establishes a new way to investigate this type of oncogenic viral infection and identifies a potential therapeutic agent against this infection. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - May 30, 2016 Category: Science Source Type: news

Identifying how Merkel cell polyomavirus infection can cause a lethal carcinoma
(University of Pennsylvania School of Medicine) A benign virus normally found in the skin can lead to a type of rare, lethal skin cancer. Specifically, infection by the Merkel cell polyomavirus can lead to Merkel cell carcinoma in immune-compromised individuals. Researchers have now identified a type of skin cell as the target of the virus in humans and establishes a new way to investigate this type of oncogenic viral infection and identifies a potential therapeutic agent against this infection. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - May 29, 2016 Category: Cancer & Oncology Source Type: news

How to Spot Skin Cancer
By Stacy Simon Skin cancer is by far the most common type of cancer. If you know what to look for, you can spot warning signs of skin cancer early. Finding it early, when it’s small and has not spread, makes skin cancer much easier to treat. Your doctor can check your skin carefully during a routine cancer-related check-up. Many doctors also recommend that you check your own skin about once a month. Look at your skin in a well-lit room in front of a full-length mirror. Use a hand-held mirror to look at areas that are hard to see. Use the “ABCDE rule” to look for some of the common signs of melanoma, the d...
Source: American Cancer Society :: News and Features - May 4, 2016 Category: Cancer & Oncology Tags: Skin Cancer - Basal and Squamous Cell Skin Cancer - Melanoma Prevention/Early Detection Skin Cancer - Merkel Cell Source Type: news

Keytruda (Pembrolizumab) Shows Promise for Advanced Merkel Cell Carcinoma
By Stacy SimonResults of a small clinical trial show that more than half the patients with Merkel cell carcinoma, a rare but aggressive type of skin cancer, improved when they took the immunotherapy drug Keytruda (pembrolizumab). And the improvement appears to be lasting longer than would be expected with standard treatment. This is a significant finding because there are currently no drugs that have been approved by the US Food and Drug Administration (FDA) to treat Merkel cell carcinoma. Researchers studying Keytruda and other drugs are trying to provide more treatment options for people with this type of skin cancer.Whi...
Source: American Cancer Society :: News and Features - May 3, 2016 Category: Cancer & Oncology Tags: Skin Cancer - Merkel Cell Source Type: news

Merkel cell carcinoma responds to first-line pembrolizumab
The objective response rate wad 56% among 25 patients... (Source: Skin and Allergy News)
Source: Skin and Allergy News - April 21, 2016 Category: Dermatology Source Type: news

Keytruda Active in Merkel Cell Cancer (CME/CE)
(MedPage Today) -- Durable responses in half of patients with advanced disease (Source: MedPage Today Dermatology)
Source: MedPage Today Dermatology - April 21, 2016 Category: Dermatology Source Type: news

'Remarkable' Responses in Rare Merkel-Cell Skin Cancer 'Remarkable' Responses in Rare Merkel-Cell Skin Cancer
The first-ever positive clinical trial in the rare Merkel-cell carcinoma shows the highest responses to immunotherapy yet seen, in 56% of patients. Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - April 20, 2016 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Drug Promising Against Rare Skin Cancer
Research suggests IV med might benefit patients with Merkel cell carcinoma (Source: WebMD Health)
Source: WebMD Health - April 19, 2016 Category: Consumer Health News Source Type: news

Drug Shows Promise Against Rare, Aggressive Skin Cancer
Research suggests IV med might benefit patients with Merkel cell carcinoma (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - April 19, 2016 Category: Cancer & Oncology Authors: webmaster at doctorslounge.com Tags: Oncology, News, Source Type: news

Drug Shows Promise Against Rare, Aggressive Skin Cancer
Research suggests IV med might benefit patients with Merkel cell carcinoma Source: HealthDay Related MedlinePlus Pages: Medicines, Melanoma, Skin Cancer (Source: MedlinePlus Health News)
Source: MedlinePlus Health News - April 19, 2016 Category: Consumer Health News Source Type: news

Drug Shows Promise Against Rare, Aggressive Skin Cancer
Research suggests IV med might benefit patients with Merkel cell carcinoma (Source: U.S. News - Health)
Source: U.S. News - Health - April 19, 2016 Category: Consumer Health News Source Type: news

Immunotherapy drug shrinks tumors in half of patients with rare, virus-linked skin cancer
(Johns Hopkins Medicine) In a clinical trial of the immunotherapy drug pembrolizumab, half of 25 patients with a rare type of virus-linked skin cancer called Merkel cell carcinoma experienced substantial tumor shrinkage lasting nearly three times as long, on average, than with conventional chemotherapy. Several patients had no remaining evidence of disease. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - April 19, 2016 Category: Cancer & Oncology Source Type: news

Merkel cell carcinoma patients who received pembrolizumab often had durable responses
(Fred Hutchinson Cancer Research Center) In a phase 2 clinical trial of the immunotherapy drug pembrolizumab as a first-line systemic therapy for advanced Merkel cell carcinoma, or MCC -- a rare, aggressive type of skin cancer -- the clinical response rate was similar to that typically seen with standard chemotherapy, but the duration of the response appeared to be markedly longer. There are currently no therapies that have been approved by the US Food and Drug Administration for this cancer. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - April 19, 2016 Category: Cancer & Oncology Source Type: news

Understanding the role of human polyomaviruses in cancer
A new method to screen tumor samples for the presence of any human polyomavirus has been created by a team of researchers. Their study found no evidence for the involvement of human polyomaviruses in the development of these cancers and helps to resolve questions in the field about whether viruses related to Merkel cell polyomavirus contribute to cancer. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - February 25, 2016 Category: Science Source Type: news

Merck, Pfizer Skin Cancer Drug Receives Breakthrough Status
FDA granted Avelumab* a Breakthrough Therapy designation for the treatment of patients with metastatic Merkel cell carcinoma (Source: PharmaManufacturing.com)
Source: PharmaManufacturing.com - November 19, 2015 Category: Pharmaceuticals Source Type: news

Initiation Of Phase III First-Line Trial Of Avelumab
The clinical development program for avelumab now includes more than 1,400 patients who have been treated across more than 15 tumor types, including breast cancer, gastric/gastro-esophageal (GEJ) cancers, head and neck cancer, Merkel cell carcinoma, melanoma, NSCLC, ovarian cancer, renal cell carcinoma and urothelial (e.g., bladder) cancer.11/05/2015 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - November 5, 2015 Category: Urology & Nephrology Source Type: news

Researchers' cure of metastatic skin cancer revealed
Metastatic Merkel-cell carcinoma is often fatal and there is no effective treatment. Now a researcher is reporting some positive results from treating this illness with a drug called idelalisib. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - October 16, 2015 Category: Science Source Type: news

Merkel cell carcinoma responds to immunotherapy
VIENNA – High response rates to pembrolizumab and to intratumoral delivery of plasmid interleukin-12 (IL-12) were observed among patients with advanced Merkel cell carcinoma (MCC), based on studies presented at the 2015 European Cancer Congress. There is strong rationale for immunotherapy in MCC.... (Source: Skin and Allergy News)
Source: Skin and Allergy News - October 9, 2015 Category: Dermatology Source Type: news

Data in Nine Difficult-to-Treat Cancers from Merck’s KEYTRUDA® (pembrolizumab) Development Program to be Presented at European Cancer Congress 2015, Including Data in Four New Cancer Types: ...
Dateline City: KENILWORTH, N.J. ...Nasopharyngeal Carcinoma, Anal Cancer, Merkel Cell Carcinoma and Biliary Tract Cancer Data to Include First-Time Findings on the Potential Importance of PD-L2 Expression in Predicting Patient Responsiveness to Anti-PD-1 Therapy KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced today that new data investigating the anti-tumor activity of KEYTRUDA® (pembrolizumab) across a broad range of advanced cancers will be presented at t...
Source: Merck.com - Product News - September 21, 2015 Category: Drugs & Pharmacology Tags: Oncology Newsroom Prescription Medicine News Research and Development News Corporate News Latest News Source Type: news

Data in Nine Difficult-to-Treat Cancers from Merck ’s KEYTRUDA® (pembrolizumab) Development Program to be Presented at European Cancer Congress 2015, Including Data in Four New Cancer Types: ...
Dateline City: KENILWORTH, N.J. ...Nasopharyngeal Carcinoma, Anal Cancer, Merkel Cell Carcinoma and Biliary Tract Cancer Data to Include First-Time Findings on the Potential Importance of PD-L2 Expression in Predicting Patient Responsiveness to Anti-PD-1 Therapy KENILWORTH, N.J.--( BUSINESS WIRE )--Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced today that new data investigating the anti-tumor activity of KEYTRUDA ® (pembrolizumab) across a broad range of advanced cancers will be presented at this year ’s European Cancer Congress (ECC) ...
Source: Merck.com - Product News - September 21, 2015 Category: Drugs & Pharmacology Tags: Oncology Newsroom Prescription Medicine News Research and Development News Corporate News Latest News Source Type: news

Merkel Cell Carcinoma: Definition, Statistics, Risk Factors and Treatment
Merkel cell carcinoma (MCC) is an uncommon form of skin cancer that begins when Merkel cells grow out of control. Merkel cells are a type of neuroendocrine cell and are also sometimes referred to as, ‘neuroendocrine carcinoma,' of a person's skin. Another name for MCC is, ‘trabecular carcinoma.' MCC is far less common than the majority of other forms of skin cancer, although it is one of the most dangerous ones. It is much more likely than common cancers to spread to other parts of a person's body if it is not caught early and may be very difficult to treat if it has spread. (Source: Disabled World)
Source: Disabled World - February 20, 2015 Category: Disability Tags: Skin Melanoma Source Type: news

Cells take sole responsibility for Merkel cell maintenance
(Rockefeller University Press) Researchers have identified a population of 'progenitor' cells in the skin that are solely responsible for the generation and maintenance of touch-sensing Merkel cells. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - January 26, 2015 Category: Cancer & Oncology Source Type: news